The HER2+ landscape treatment can count on multiple HER2-targeting monoclonal antibodies, HER2-targeted ADCs, which have proven to be promising in the clinical setting; for example, T-DXd became the second line of treatment for HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.